Showing 20 of 46 recruiting trials for “splenic-marginal-zone-lymphoma”
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
RecruitingNCT06534463 ↗
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
👨⚕️ Bing Xu, The First Aiffiliated hosptical of xiamen University📍 1 site📅 Started Jun 2024View details ↗
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
👨⚕️ Preetesh Jain, MBBS, MD, DM, PhD, M.D. Anderson Cancer Center📍 1 site📅 Started May 2024View details ↗
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
RecruitingNCT05700149 ↗
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
👨⚕️ Davide Rossi, MD, Oncology Institute of Southern Switzerland and Institute of Oncology Research📍 36 sites📅 Started Apr 2024View details ↗
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
👨⚕️ Yucai Wang, Academic and Community Cancer Research United📍 2 sites📅 Started Jan 2024View details ↗
The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
👨⚕️ Jun Shi, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University📍 1 site📅 Started Nov 2023View details ↗
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
👨⚕️ Catherine THIEBLEMONT, Pr, Lymphoma Study Association📍 48 sites📅 Started Sep 2023View details ↗
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Clinical Study of OR for Second-line Treatment of Refractory MZL
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →